BeStock  
Stocks › Biotechnology › RAPP

Rapport Therapeutics RAPP

US equityMarket cap rank #2939Biotechnology
$23.16 −$0.43 (-1.82%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $23.16 0.00%
Open$23.23
Prev close$23.59
Day range$23.00 – $23.83
Volume437.7K
Market cap$1.37B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$0.00
Operating profit-$44.09M-47.0% YoY
Net profit-$40.24M-49.4% YoY
Diluted EPS-$0.84-18.3% YoY
Free cash flow-$41.63M-136.6% YoY
Operating cash flow-$41.63M

Revenue, last 8 quarters

$0.0Dec '24$0.0Mar '25$0.0Jun '25$0.0Sep '25$0.0Dec '25$20.0MMar '26$0.0Jun '26$0.0Sep '26

Net profit, last 8 quarters

$-20.0MDec '24$-24.1MMar '25$-26.7MJun '25$-26.9MSep '25$-33.8MDec '25$-19.9MMar '26$-56.6MJun '26$-40.2MSep '26

Diluted EPS by quarter

-0.57Dec '24-0.68Mar '25-0.75Jun '25-0.71Sep '25-0.72Dec '25-0.42Mar '26-1.19Jun '26-0.84Sep '26

Free cash flow by quarter

$-14.7MDec '24$-20.5MMar '25$-25.1MJun '25$-17.6MSep '25$-24.9MDec '25$-13.1MMar '26$-41.5MJun '26$-41.6MSep '26

Annual revenue

$0.0FY23$0.0FY24$0.0FY25

Profitability & balance sheet

Operating margin-838.1%
Net margin-752.4%
Return on equity-33.3%
Return on assets-31.5%
Return on invested capital-36.3%
Current ratio20.07
Liabilities / assets6.5%
Cash & investments$395.03M
Total debt$7.07M
Net cash (debt)$387.96M

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Operating Revenue $0.00 $0.00 $20.00M $0.00 $0.00
Operating Expense $44.09M $60.81M $44.22M $125.10M $38.51M
Selling and Admin Expenses $9.77M $9.39M $11.50M $30.31M $8.25M
-General & Admin Expense $9.77M $9.39M $11.50M $30.31M $8.25M
Research & Development $34.32M $51.41M $32.72M $94.79M $30.26M
Operating Profit -$44.09M -$60.81M -$24.22M -$125.10M -$38.51M
Net Non-Operating Interest Income (Expense) $3.85M $4.19M $4.36M $13.62M $4.75M
Non-Operating Interest Income $3.85M $4.19M $4.36M $13.62M $4.75M
Pretax Profit -$40.24M -$56.62M -$19.86M -$111.48M -$33.76M
Net Profit -$40.24M -$56.62M -$19.86M -$111.48M -$33.76M
Profit from Continuing Operations -$40.24M -$56.62M -$19.86M -$111.48M -$33.76M
Net Income to Parent Company -$40.24M -$56.62M -$19.86M -$111.48M -$33.76M
Net Income to Common Stockholders -$40.24M -$56.62M -$19.86M -$111.48M -$33.76M
Basic EPS -$0.84 -$1.19 -$0.42 -$2.86 -$0.72
Diluted EPS -$0.84 -$1.19 -$0.42 -$2.86 -$0.72
Total Revenue as Reported – $0.00 $20.00M – –

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $418.56M $458.98M $497.60M $512.43M $512.43M
Total Current Assets $407.38M $446.86M $484.70M $498.56M $498.56M
Cash and Cash Equivalents & Short-Term Investments $395.03M $436.08M $476.78M $490.54M $490.54M
-Cash and Cash Equivalents $74.75M $63.61M $78.06M $52.65M $52.65M
-Short Term Investments $320.28M $372.47M $398.73M $437.89M $437.89M
Receivables $171,000.00 $293,000.00 $58,000.00 – –
-Accounts Receivable $171,000.00 $293,000.00 $58,000.00 – –
Restricted Cash $105,000.00 $105,000.00 $105,000.00 $105,000.00 $105,000.00
Other Current Assets $12.08M $10.38M $7.75M $7.92M $7.92M
Total Non-Current Assets $11.18M $12.13M $12.90M $13.87M $13.87M
Net PPE $10.08M $11.07M $11.85M $12.89M $12.89M
-Gross PPE $12.20M $13.21M $13.78M $14.87M $14.87M
-Accumulated Depreciation -$2.12M -$2.14M -$1.93M -$1.98M -$1.98M
Other Non-Current Assets $1.10M $1.06M $1.06M $985,000.00 $985,000.00
Total Liabilities $27.37M $36.06M $26.09M $27.78M $27.78M
Total Current Liabilities $20.30M $28.42M $17.90M $19.05M $19.05M
Payables $1.72M $2.80M $6.56M $4.19M $4.19M
-Accounts Payable $1.72M $2.80M $6.56M $4.19M $4.19M
Current Accrued Expenses $10.61M $18.91M $5.65M $4.98M $4.98M
Short-Term Debt and Capital Lease Obligation $2.33M $2.47M $2.62M $2.76M $2.76M
-Current Capital Lease Obligation $2.33M $2.47M $2.62M $2.76M $2.76M
Total Non-Current Liabilities $7.07M $7.63M $8.19M $8.73M $8.73M
Long Term Debt and Capital Lease Obligation $7.07M $7.63M $8.19M $8.73M $8.73M
-Long Term Capital Lease Obligation $7.07M $7.63M $8.19M $8.73M $8.73M
Total Equity $391.19M $422.93M $471.51M $484.65M $484.65M
Stockholders' Equity $391.19M $422.93M $471.51M $484.65M $484.65M
Capital Stock $48,000.00 $48,000.00 $48,000.00 $48,000.00 $48,000.00
-Common Stock $48,000.00 $48,000.00 $48,000.00 $48,000.00 $48,000.00
-Preferred Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $745.19M $735.85M $727.05M $719.29M $719.29M
Retained Earnings -$351.94M -$311.70M -$255.09M -$235.23M -$235.23M
Gains/Losses Not Affecting Retained Earnings -$2.12M -$1.27M -$505,000.00 $546,000.00 $546,000.00

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$41.63M -$41.46M -$13.06M -$87.47M -$24.70M
Net cash flow from continuing operations -$41.63M -$41.46M -$13.06M -$87.47M -$24.70M
Net Income from Continuing Operations -$40.24M -$56.62M -$19.86M -$111.48M -$33.76M
Gain/Loss from Continuing Operations -$15,000.00 -$1,000.00 $153,000.00 – –
Depreciation & Depletion & Amortization $198,000.00 $212,000.00 $227,000.00 $1.02M $265,000.00
Other Non-Cash Items $608,000.00 $595,000.00 $582,000.00 $2.03M $571,000.00
Change in Working Capital -$9.47M $6.81M -$765,000.00 $3.50M $3.61M
-Change in Receivables $122,000.00 -$235,000.00 -$58,000.00 – –
-Change in Prepaid Assets -$855,000.00 -$3.16M $814,000.00 -$3.60M -$987,000.00
-Change in Payables and Accrued Expense -$8.02M $10.90M -$1.19M $8.38M $4.86M
-Change in Other Current Assets -$2,000.00 $0.00 $346,000.00 -$791,000.00 $119,000.00
-Change in Other Current Liabilities -$716,000.00 -$698,000.00 -$681,000.00 -$491,000.00 -$389,000.00
Net cash flow from investing $51.06M $25.60M $37.94M -$187.47M -$174.32M
Net Cash Flow from Continuing Investing Activities $51.06M $25.60M $37.94M -$187.47M -$174.32M
Net PPE Purchase and Sale $208,000.00 $115,000.00 -$86,000.00 -$616,000.00 -$169,000.00
Net Investment Purchase and Sale $50.86M $25.49M $38.03M -$186.86M -$174.16M
Financing Cash Flow $1.71M $1.41M $531,000.00 $270.79M $311,000.00
Net Cash Flow from Continuing Financing Activities $1.71M $1.41M $531,000.00 $270.79M $311,000.00
Net Common Stock Issuance $0.00 $0.00 -$5,000.00 $269.44M -$395,000.00
Proceeds from Stock Option Exercised $1.71M $1.59M $809,000.00 $1.35M $706,000.00
Net Other Financing Charges $1,000.00 -$181,000.00 -$273,000.00 – –
Ending Cash Balance $74.86M $63.72M $78.16M $52.75M $52.75M
Net Change in Cash $11.14M -$14.44M $25.41M -$4.16M -$198.71M
Beginning Cash Balance $63.72M $78.16M $52.75M $56.91M $251.46M
Free Cash Flow -$41.63M -$41.53M -$13.15M -$88.09M -$24.87M
Net Preferred Stock Issuance – – – $0.00 $0.00

Discussion

No comments yet — be the first to weigh in on RAPP.

Sign in to join the discussion.

Scroll to Top